Myeloproliferative Neoplasms

Bone Fracture Risk Increased in Patients With Myeloproliferative Neoplasms

By

Susan Moench, PhD, PA-C

Publish Date October 7, 2020

Retrospective analysis sought to determine incidence of hip and vertebral fractures in patients with MPN compared with that of the general population.

Interferon Alpha and Pegylated Interferon Alpha Can Be Safe, Effective for Treatment of Essential Thrombocythemia and Polycythemia Vera

By

Susan Moench, PhD, PA-C

Publish Date October 5, 2020

Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.

Germline Factors Affect Molecular Response to Treatment for Polycythemia Vera

By

Patricia Chaney

Publish Date September 29, 2020

Germline polymorphisms can affect response to treatment in people with polycythemia vera.

Molecular Profiling Can Assess Risk for Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis

By

Jessica Nye, PhD

Publish Date September 16, 2020

Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.

Assessment of Organ Elasticity as a Surrogate for Bone Marrow Fibrosis in Myeloproliferative Neoplasms

By

Susan Moench, PhD, PA-C

Publish Date September 4, 2020

Spleen stiffness was found to be correlated with the extent of bone marrow fibrosis, as well as clinical outcome, in patients with MPNs.